China Regenerative Medicine International Limited

SEHK:8158 Stock Report

Market Cap: HK$95.8m

China Regenerative Medicine International Valuation

Is 8158 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8158 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8158 (HK$0.32) is trading below our estimate of fair value (HK$2.87)

Significantly Below Fair Value: 8158 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8158?

Key metric: As 8158 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8158. This is calculated by dividing 8158's market cap by their current revenue.
What is 8158's PS Ratio?
PS Ratio1.7x
SalesHK$55.06m
Market CapHK$95.84m

Price to Sales Ratio vs Peers

How does 8158's PS Ratio compare to its peers?

The above table shows the PS ratio for 8158 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.4x
8247 Biosino Bio-Technology and Science Incorporation
0.4xn/aHK$115.8m
6628 Transcenta Holding
13x67.8%HK$311.7m
2197 Clover Biopharmaceuticals
11.7xn/aHK$363.2m
1228 CANbridge Pharmaceuticals
0.6xn/aHK$66.3m
8158 China Regenerative Medicine International
1.7xn/aHK$95.8m

Price-To-Sales vs Peers: 8158 is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (6.4x).


Price to Sales Ratio vs Industry

How does 8158's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.11.2x29.3%
8158 China Regenerative Medicine International
1.7xn/aUS$12.31m
6826 Shanghai Haohai Biological Technology
2.1x11.8%US$1.79b
1530 3SBio
1.4x9.3%US$1.67b
8158 1.7xIndustry Avg. 11.2xNo. of Companies14PS01632486480+
14 CompaniesEstimated GrowthMarket Cap
Industry Avg.11.2x42.6%
8158 China Regenerative Medicine International
1.7xn/aUS$12.31m
No more companies

Price-To-Sales vs Industry: 8158 is good value based on its Price-To-Sales Ratio (1.7x) compared to the Hong Kong Biotechs industry average (11.2x).


Price to Sales Ratio vs Fair Ratio

What is 8158's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8158 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8158's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies